{
  "ticker": "FOLD",
  "company_name": "Amicus Therapeutics",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02675465",
      "title": "First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Pompe Disease",
      "start_date": "2016-04",
      "completion_date": "2024-08-22",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT00813865",
      "title": "A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1",
      "start_date": "2009-05-11",
      "completion_date": "2012-05-01",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT00283959",
      "title": "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Fabry Disease",
      "start_date": "2006-06-27",
      "completion_date": "2008-05-08",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT03135197",
      "title": "German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Fabry Disease",
      "start_date": "2017-06-08",
      "completion_date": "2020-06-30",
      "enrollment": 0,
      "sponsor": "University Hospital Muenster"
    },
    {
      "nct_id": "NCT04602364",
      "title": "French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Fabry Disease",
      "start_date": "2020-10-15",
      "completion_date": "2023-06-30",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics France SAS"
    },
    {
      "nct_id": "NCT04804566",
      "title": "Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Fabry Disease",
      "start_date": "2023-03-01",
      "completion_date": "2023-11-01",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT02363153",
      "title": "Diet and Exercise in Pompe Disease",
      "status": "COMPLETED",
      "phase": "NA",
      "condition": "Pompe Disease, Glycogen Storage Disease Type II, Lysosomal Storage Diseases",
      "start_date": "2017-11-06",
      "completion_date": "2021-05-12",
      "enrollment": 0,
      "sponsor": "University of Florida"
    },
    {
      "nct_id": "NCT04808505",
      "title": "A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Glycogen Storage Disease Type II Infantile Onset",
      "start_date": "2023-07-18",
      "completion_date": "2027-04",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT06904261",
      "title": "A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Fabry Disease",
      "start_date": "2025-12",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT06303466",
      "title": "Real World Evidence Study of Danish Fabry Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "",
      "condition": "Fabry Disease",
      "start_date": "2023-08-01",
      "completion_date": "2024-12-31",
      "enrollment": 0,
      "sponsor": "Caroline Michaela Kistorp"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1, PHASE2": 1,
      "PHASE2": 12,
      "": 17,
      "NA": 2,
      "PHASE3": 13,
      "PHASE1": 5
    },
    "by_status": {
      "COMPLETED": 32,
      "RECRUITING": 5,
      "ACTIVE_NOT_RECRUITING": 2,
      "AVAILABLE": 3,
      "TERMINATED": 6,
      "NOT_YET_RECRUITING": 1,
      "UNKNOWN": 1
    },
    "active_trials": 7,
    "completed_trials": 32,
    "conditions": [
      "Epidermolysis Bullosa",
      "Fabry Disease",
      "Fabry Disease, Anderson Fabry Disease",
      "Fabry Disease, Heart Diseases",
      "Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1",
      "Gaucher Disease, Type 1, Type 1 Gaucher Disease, Gaucher Disease",
      "Glycogen Storage Disease Type II Infantile Onset",
      "Hypertrophic Cardiomyopathy, Endothelial Dysfunction",
      "Late-onset Pompe Disease",
      "Pompe Disease",
      "Pompe Disease (Late-onset)",
      "Pompe Disease Infantile-Onset",
      "Pompe Disease, Glycogen Storage Disease Type II",
      "Pompe Disease, Glycogen Storage Disease Type II, Lysosomal Storage Diseases",
      "Pompe Disease, Hypersensitivity Reaction",
      "Type 1 Gaucher Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:38.326568",
    "search_query": "Amicus Therapeutics",
    "url": "https://clinicaltrials.gov/search?term=Amicus+Therapeutics"
  }
}